BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $54
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.